Laviana Pharma, a CRO/CMO with subsidiaries in Beijing and Tianjin, plus a business office in the US, closed a $15 million Series B funding led by Shenzhen Huayi Capital. Founded in 2005 by returnees, Laviana provides outsourced small molecule process and manufacturing services to pharmaceutical companies. In 2016, Laviana listed shares on China’s NEEQ, an OTC exchange that lists shares without raising any capital for companies.
Source: China Biotoday
